Evidence map›Paper›PMID 31016860›Full record

ReviewStem cells translational medicine2019

Concise Review: Exploiting Unique Biological Features of Leukemia Stem Cells for Therapeutic Benefit.

Haojian Zhang, Shaoguang Li

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cells translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Haojian ZhangThe State Key Laboratory Breeding Base of Basic Science of Stomatology, Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan, People's Republic of China.
Shaoguang LiDivision of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.ORCID 0000-0002-8947-9614
University of Massachusetts Chan Medical School · USWuhan University · CN

Funding

Developing a novel therapeutic strategy for overcoming TKI resistance in ALLR01CA222590 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LI, SHAOGUANG · 2018 to 2022
$2.4M
Zileuton as a chemopreventive agent for chronic myeloid leukemiaR01CA176179 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LI, SHAOGUANG · 2014 to 2018
$1.7M
A novel genetic pathway for survival of B-lymphoblastic leukemia-initiating cellsR21CA209298 · NCI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI LI, SHAOGUANG · 2018 to 2019
$395k
NCI NIH HHS R01 CA176179NCI NIH HHS R01 CA222590NCI NIH HHS R21 CA209298
6 · The paper itself

Abstract

Cancer stem cells play a critical role in disease initiation and insensitivity to chemotherapy in numerous hematologic malignancies and some solid tumors, and these stem cells need to be eradicated to achieve a cure. Key to successful targeting of cancer stem cells is to identify and functionally test critical target genes and to fully understand their associated molecular network in these stem cells. Human chronic myeloid leukemia (CML) is well accepted as one of the typical types of hematopoietic malignancies that are derived from leukemia stem cells (LSCs), serving as an excellent model disease for understanding the biology of LSCs and developing effective, selective, and curative strategies through targeting LSCs. Here, we discuss LSCs in CML with a focus on identification of unique biological features of these stem cells to emphasize the feasibility and significance of specific targeting of LSCs while sparing normal stem cell counterparts in leukemia therapy. Stem Cells Translational Medicine 2019;8:768&774.

Indexed as

AnimalsAntineoplastic AgentsHumansLeukemia, MyeloidNeoplastic Stem CellsAntineoplastic AgentsBCR-ABLBone marrowCancer stem cellsChronic myeloid leukemiaLeukemia

Identifiers

PMID31016860
PMCPMC6646691
OpenAlexW2941402354

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.